HSP

Kirby McInerney LLP is investigating potential claims against Hospira, Inc. (“Hospira” or the “Company”) (NYSE:HSP) concerning the proposed acquisition of the Company by Pfizer Inc. (“Pfizer”) (NYSE:PFE). Under the terms of the definitive merger agreement, Hospira stockholders will receive $90.00 in cash for each share of Hospira common stock they own, valuing the transaction at a total enterprise value of approximately $17 billion.

The investigation concerns whether the Hospira Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values the Company’s common stock.

If you are a Hospira stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, or telephone at (212) 699-1145, Melissa Fortunato, Esq. by email at mfortunato@kmllp.com, or telephone at (212) 699-1141, or toll free at (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

Kirby McInerney LLPJ. Brandon Walker, Esq., 212-699-1145bwalker@kmllp.comorMelissa Fortunato, Esq., 212-699-1141mfortunato@kmllp.com

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024